American Peptide to benefit from merger

01 August 2008 22:48  [Source: ICIS news]

By Feliza Mirasol

NEW YORK (ICIS news)--American Peptide Company will establish a stronger foothold in the global pharmaceutical and biotechnology markets following its acquisition by Otsuka Chemical, American Peptide’s president said on Friday.

“This is an important deal for Otsuka Chemical and APC. We will continue to be a strong peptide CMO [contract manufacturing organisation],” said Takahiro Ogata, president and chief operating officer of American Peptide.

Under Otsuka Chemical, American Peptide will have access to expanded global networking opportunities and more financial resources for its production and manufacturing facilities, Ogata added.

On Wednesday, American Peptide announced that its parent company, Ito Life Sciences, would be acquired by Otsuka Chemical for an undisclosed amount. The deal is expected to close on 1 September.

The acquisition was timely, Ogata said. American Peptide is growing at around 15-20%/year and its customers are growing in terms of both volume and scale, he added.

American Peptide carries its pharmaceutical and biotechnology customers from preclinical through commercial manufacturing stages.

American Peptide is in the midst of expanding its cGMP (current good manufacturing practices) manufacturing facility in Vista, California. The expansion is expected to be complete by the first quarter of 2009.

Sign up for the ICIS Fine and Pharmaceutical Chemicals e-newsletter at www.icis.com/e-newsletters
To discuss issues facing the chemical industry go to ICIS connect

By: Feliza Mirasol
+1 713 525 2653

For the latest chemical news, data and analysis that directly impacts your business sign up for a free trial to ICIS news - the breaking online news service for the global chemical industry.

Get the facts and analysis behind the headlines from our market leading weekly magazine: sign up to a free trial to ICIS Chemical Business.

Printer Friendly